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COMMENTARY Open Access
The successful implementation of Scotland’s
Hepatitis C Action Plan: what can other European
stakeholders learn from the experience? A Scottish
voluntary sector perspective
Leon Wylie1*, Sharon Hutchinson2, David Liddell3, Nicola Rowan4
In 2004, the Scottish government declared that “Hepatitis
C is one of the most serious and significant public health
risks of our generation” [1]. Social and political recognition
of the scale of the problem, and of its strong links to
health inequalities, spurred policy-makers to allocate
significant government funding to a nationally coordinated
Hepatitis C Action Plan [2], with an evidence-gathering
and consultation phase followed by a planning and action
phase.
It appears that the successful implementation of the
Hepatitis C Action Plan, coupled with an increase in the
availability of addiction treatment, has contributed to a
significant decline in hepatitis C virus (HCV) incidence,
sharp increases in the numbers of people accessing HCV
treatment and achieving sustained viral response, and an
overall decrease in population prevalence of HCV [3]. The
Scottish Action Plan is reflected in many interventions
promulgated in ECDC and ECDDMA Guidance:
Prevention and Control of Infectious Diseases among
People Who Inject Drugs [4] and is a country-level
example of evidence-based interventions being effective
in practice. This commentary highlights the example set
by Scotland in its national approach to hepatitis C and
identifies voluntary sector actions and other key ele-
ments that contributed to the overall success of the two
phases of the action plan.
In 2008–2009, approximately 39,000 people in Scotland
were estimated to be chronically infected with HCV, and
the overall HCV prevalence rate amongst people who
were either currently injecting drugs or had injected drugs
in the past stood at about 60% [3]. The identification of
HCV as a priority public health risk in Scotland and the
development of an effective response were outcomes of a
unique collaboration of public health, university and
patient representative organisations. This partnership,
driven by Health Protection Scotland, used scientific and
political pressure to ensure that HCV was addressed in a
serious, practical and, importantly, whole-of-country
manner.
Voluntary sector organisations, representing people
affected by HCV and the services that supported them,
were particularly active in raising political awareness of
the human impact of the illness and also its links to
inequalities. One of those organisations, the UK Hepatitis
C Resource Centre (UKHCRC), was the forerunner
of Hepatitis Scotland. The UKHCRC ‘s parliamentary
lobbying work, alongside the Hepatitis C Trust and other
Scottish charities such as the Scottish Drugs Forum,
informed the political environment regarding the direct
impact the illness has on patient lives and helped generate
the cross-party consensus necessary to support subsequent
funding and policy initiatives.
During Phase I of the Action Plan, it was estimated that
the number of people newly acquiring HCV each year
through injecting drug use was between 1,000 and 1,500
[2][5]. With HCV antibody testing only available since
1991 and with positive diagnoses often made many years
after infection, trends in HCV incidence in Scotland
cannot easily be inferred from currently diagnosed cases
[6].The Scottish HCV epidemic may have its roots in
the rapid explosion in intravenous drug use across Europe
in the early 1980s, with the primary catalyst being an
influx of opiates from western Asian sources such as
Afghanistan [7].
Although National Health Service (NHS) regional
boards were treating a limited number of HCV patients in
the early 2000s, modelling by Health Protection Scotland
indicated that treatment was not reaching enough people
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to have a major impact on the growing burden of liver
disease [8]. The number of prison inmates being treated
for HCV was very low [3], especially considering the high
number of incarcerated people who inject drugs and the
consequently high HCV prevalence rate in prisons [9].
There was significant variation in the distribution of
needles/syringes and other injecting paraphernalia, as
well as in the nature of educational and harm reduction
interventions offered by needle exchange services across
Scotland [10].The provision of opioid substitution treat-
ment (OST) also varied, ranging from the relatively low
threshold supply in the Edinburgh region to some rural
areas with waiting times of more than 18 months from
initial contact to treatment initiation [11].
Key researchers across the United Kingdom were
involved in the first “evidence-gathering” phase of the
action plan. This built the evidence, systems and infra-
structure for Phase II, which introduced 34 high-level
strategic actions that aimed to improve prevention,
diagnosis, treatment, care and support services using a
nationally co-ordinated approach.
An important factor in staging an appropriate public
health response is adequate funding. The careful cultiva-
tion of political support, based on evidence-gathering and
patient-based advocacy, was rewarded with initial Scottish
government ring-fenced funding of £4 million for the first
phase of the plan, followed by £43 million for the second
phase. The use of these funds was tied to strict project tar-
gets based around hepatitis testing and treatment and to a
stepwise change in the distribution of clean injecting
equipment. This new funding was in addition to funds
then being used for Hepatitis C treatment by the regional
NHS units.
Another key factor in the success of the plan was the
project management approach adopted by the decision-
makers from the beginning. Under this approach it was
acknowledged that it was likely to be most effective to set
and attain achievable goals firmly based in evidence-based
practice, even if at times these goals were not as extensive
as all would wish. The project management approach con-
trolled ongoing costs, as well as gaining very significant
cost savings through national collective bargaining for
HCV medication and injecting equipment.
Overall coordination, overseen by a national coordinat-
ing group, was tasked to three sector working groups and
was enhanced by the implementation of local Managed
Care Networks (MCNs). An MCN is a multidisciplinary
group, including voluntary sector representatives if
available, responsible for a health district’s strategic
approach. National guidance documents were produced
by task-specific working groups led by key experts, using
an evidence-led nationally consultative approach. An
important outcome of the evidence-gathering phase was
the building and refinement of information systems that
informed – and continue to inform – many aspects of
strategic direction. The expansion in data-gathering cap-
ability affords a continuing real-time comparison and ana-
lysis of regional incidence, prevalence and treatment-
related data trends.
At the national substance use policy level, which
falls under the purview of the Scottish Executive Justice
Department rather than the Scottish Executive Health
Department, increasing concerns about drug-related deaths
and poor treatment outcomes for substance users led to
recognition that the provision of OST was dependent on
which health board area was the treatment provider. A
national target for OST waiting time was introduced in
2008; this produced synergies with other preventative
measures associated with the Action Plan [12].
The relative success of the Scottish Action Plan, as
recent evidence suggests, has provided a working model
for other countries to follow [13]. The incidence of HCV
infection among people who inject drugs across Scotland
was estimated to have been reduced, potentially by as
much as half within a matter of a few years [14]. The
concomitant increase in HCV treatment initiation (from
468 cases in 2007–2008 to 1,052 cases in 2012–2013) has
also contributed to an overall decrease in HCV prevalence
in Scotland, to approximately 38,000 cases in 2012 [3].
There has been a large increase in HCV testing in drug
services [15], and hence a greater number of patients who
access treatment are from marginalised populations.
Prison inmates comprise 11% of those treated, up from
four percent in 2007–2008 [3].
It is also recognised that this Action Plan would not
have been as effective without serious government invest-
ment. The Action Plan approach has been of benefit to
ever greater numbers of patients, and given the wide varia-
tion or lack of effective national policy approaches to HCV
across Europe, the lessons learnt by Scotland in harnessing
voluntary sector, health and university institutions to drive
forward political consensus can be used to further develop
a pan-European strategic approach to HCV.
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